<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18298">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01885910</url>
  </required_header>
  <id_info>
    <org_study_id>IIT-000508</org_study_id>
    <nct_id>NCT01885910</nct_id>
  </id_info>
  <brief_title>Use of Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel Treatment</brief_title>
  <official_title>Use of Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Derm Research, PLLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>WFH MEDICAL, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Derm Research, PLLC</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study will explore if continuation of treatment of treatment with Aczone 5% gel
      following combination treatment with with doxycycline and Aczone 5% gel can maintain
      therapeutic response.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Investigator Global Assessment (IGA) of acne vulgaris</measure>
    <time_frame>Every 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory and non-inflammatory lesion counts</measure>
    <time_frame>Every 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acne Vulgaris</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline 100mg and Aczone 5% gel</intervention_name>
    <description>Subject is to take Doxycycline 100mg by mouth once daily and apply Aczone 5% gel to their face twice daily for 12 weeks; those subjects achieving treatment response will stop Doxycycline and continue applying Aczone 5% gel twice daily for 12 more weeks.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatient, male or female subjects of any race, age 12 or older.  Female subjects of
             childbearing potential must have a negative urine pregnancy test result at Baseline
             and practice a reliable method of contraception throughout the study;

          -  Facial acne vulgaris characterized by the following:

        IGA Score &gt;3 10-50 facial inflammatory lesions (papules,pustules) 10-100 facial
        non-inflammatory lesions (open/closed comedones)

          -  Able to understand and comply with the requirements of the study and sign Informed
             Consent/HIPAA Authorization forms

        Exclusion Criteria:

          -  Female subjects who are pregnant (positive urine pregnancy test), breast feeding, or
             who are of childbearing potential and not practicing a reliable method of birth
             control.

          -  Allergy/sensitivity to any component of the test treatment (Section 5.2), lincomycin,
             tetracyclines, or sulfites.

          -  Subjects who have not complied with the proper wash-out periods for prohibited
             medications/procedures (Supplement 1)&gt;

          -  History of clinically significant anemia or hemolysis.

          -  History of enteritis (regional enteritis, ulcerative colitis, pseudomembranous
             colitis, or antibiotic-associated colitis).

          -  Skin disease/disorder that might interfere with the diagnosis or evaluation of acne
             vulgaris

          -  Evidence of recent alcohol or drug abuse

          -  Medical condition that, in the opinion of the Investigator, contraindicates the
             subject's participation in the clinical study

          -  History of poor cooperation, non-compliance with medical treatment or unreliability

          -  Participation in an investigational drug study within 30 days of the baseline visit.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>DermResearch, PLLC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 16, 2014</lastchanged_date>
  <firstreceived_date>June 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dapsone</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Doxycycline hyclate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
